
Brokerage Wells Fargo initiates coverage on medtech firm LeMaitre Vascular LMAT.O with an "equal weight" rating and a PT of $95
Brokerage says LMAT could be poised for growth in 2025 if it pursues strategic mergers and acquisitions; adds that the company has $300 million available for deals that could bolster its device portfolio
Wells Fargo observes LMAT may acquire companies that make surgical sealants, devices that block blood flow and clips for tying off blood vessels
"We believe that the stock fully prices in an optimistic outlook for pricing and volume growth in 2025 and beyond" - brokerage
Stock up about 55% in the last 12 months